Registered forecast
85% registered probability event by 2027-02-07 Unresolved
FDA approves Verastem’s NDA for the AVMAPKI FAKZYNJA CO-PACK Blister Pack (avutometinib tablets; defactinib tablets) on or before the disclosed PDUFA goal date of 2027-02-07
FF-066 Registered - Our estimate
- 85% an estimate, not a reading
- Action by
- 2027-02-07 known at this date
- Reading window
- 2026-11-11 → 2027-02-07 known at this date
- Decision stage
- 5 Guideline
- 6 Regulatory
- 7 Coverage
- Baselines it has to beat
-
- Authority base rate 85%
- Calendar cycle 80%
- Analyst proxy 85%
- Known at this date
- The registered estimate, uncertain
- Not yet knowable at this date
At this date the record was registered at 85% and the deadline had not been reached. The outcome was not yet knowable.
The outcome is not yet knowable at this date.
nextconsensus.com/forecast/ff-066/ registry snapshot 2026-11-21 Share image
NextConsensus registered this probability on 2026-11-10. It is one of 36 registered FDA goal-date forecasts.
The proposition
What was registered
The FDA takes an approval action on Verastem, Inc.’s New Drug Application for the AVMAPKI FAKZYNJA CO-PACK Blister Pack, the co-packaged presentation of avutometinib tablets and defactinib tablets, with an approval action date on or before 2027-02-07, the PDUFA date disclosed in Verastem’s Q3 2026 results release and presentation filed 2026-11-05.
- Who decides
- US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (US)
- Who has to act
- Rung 6: Regulatory action — Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.
- Counted with
- FDA action by goal date
- Scope
- Co-packaged tablet presentation of the regimen approved for KRAS-mutated recurrent low-grade serous ovarian cancer
The estimate
Our estimate and what it has to beat
The estimate that the named body takes the action by the deadline, from what was public at the cutoff.
The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.
ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. Applications for a new dosage form of a drug the same sponsor already markets, at the approved dose, are approved at their first goal date in a large majority of cases; the complete responses that do occur are mostly on manufacturing or bioequivalence. The calendar's own met-goal-date share for disclosed PDUFA dates does not exist yet.
A clock-only model: the goal date is inside the window, FDA meets most goal dates, and most first-cycle actions on applications under Priority Review are approvals. With no evidence input it cannot tell a formulation change from a new molecule.
An analyst reading the same filings on 2026-11-10 would weigh a formulation and packaging change at the approved dose, Priority Review and a sponsor with an approved product, against new-tablet manufacturing risk and a small sponsor. Estimated by reconstructing that read, not by surveying analysts.
Regulatory action (FDA): offered on judgment, with no calibration figure until 15 in the class have resolved.
The method and every record are public, so you can check the work.
The clock
Dates that constrain the record
- Evidence as of
- 2026-11-10
Nothing after this date informed the estimate. known at this date - Registered
- 2026-11-10
Frozen and hashed. known at this date - Reading window
- 2026-11-11 → 2027-02-07
When the outcome can be read against the rule. known at this date - Event by
- 2027-02-07
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar known at this date
7a529f4585bb6406a54128ef8e7cfe782f889f95fbaa191a828c0a4e5d0ba3c5 · operator record jc-1794354011667-afda478c Around this record
- This kind of deadline
Confidential Asset & Milestone Evaluation
Evaluating an asset or milestone that the FDA could move?
Name the asset, the deciding authority, and the date your team prepares for: a P&T review, an HTA submission, a label negotiation, a deal closing, or a milestone dispute. It can be an asset you sponsor, evaluate, finance, advise on, or rely on. Every commercial evaluation applies the same pre-registration standard and primary-source verification as this record, delivered privately under mutual NDA.
Resolution
How we’ll check the result
The application number of the Blister Pack NDA was not public at the cutoff, and openFDA listed only NDA219616, the marketed CO-PACK of avutometinib capsules and defactinib tablets, for the applicant and for either ingredient (SRC-005, SRC-006, SRC-007). The adjudicator identifies the qualifying approval by its content, never by a name the adjudicator infers: an approval action that approves avutometinib in a tablet dosage form, co-packaged with defactinib tablets, under any applicant (Verastem, Inc. or a Verastem subsidiary or licensee) and any proprietary name. It may appear as the ORIG submission of a new application or as a supplement to NDA219616; either counts. The capsule presentation approved in 2025 does not count. Resolves YES if the openFDA Drugs@FDA records returned by https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22AVUTOMETINIB%22&limit=100 and by https://api.fda.gov/drug/drugsfda.json?search=sponsor_name:%22VERASTEM+INC%22&limit=100, read together, contain such an approval: a submission with submission_status AP and a submission_status_date on or before 2027-02-07, confirmed as the tablet presentation by its product listing, approval letter or label. An approval for a narrower population or fewer dose packs than the applicant sought still resolves YES. A tentative approval does not count. Resolves NO if no approval action is dated on or before 2027-02-07: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2027-02-07 resolves NO as occurred_after_deadline. 2027-02-07 is a Sunday; an approval action dated on the preceding Friday or earlier counts. Read no earlier than 2027-02-21. If openFDA has not refreshed by then, or both queries return no qualifying record, the Drugs@FDA web record (https://www.accessdata.fda.gov/scripts/cder/daf/, searched by the names avutometinib, defactinib and AVMAPKI) governs, under the same identification test. Resolves unresolvable only if none of these sources can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.
Source the rule names: https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22AVUTOMETINIB%22&limit=100, https://api.fda.gov/drug/drugsfda.json?search=sponsor_name:%22VERASTEM+INC%22&limit=100, https://www.accessdata.fda.gov/scripts/cder/daf/
After the deadline, the founder (Kanav Jain) reads the outcome against the frozen public source; unratified automated readings are labelled machine-resolved and excluded from class calibration figures.
What this record will show once it resolves
Beside every result, the count for its class (FDA action by goal date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.
- The finding
- As the rule above reads it: occurred on time, did not occur, or left unscored.
- The readers and their sources
- After the deadline, the founder (Kanav Jain) reads the frozen public source named above under the registered rule (or automated checks record a machine-resolved reading). Who adjudicated it and the source read are published here so any reader can verify the outcome. Adjudication applies the frozen rule to the named public source so any reader can verify the reading independently.
- The number against its baselines
- 85% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.
Reasoning
What the number rests on
The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record, are held in the ledger, and are covered by its hash.
The state of the record at the cutoff
Recorded as they stood on 2026-11-10.
- review pathway
- Priority Review, granted at acceptance on 2026-10-07 (SRC-001, SRC-002). Center CDER is the drafter's understanding (a small-molecule NDA), unverified.
- submission type
- New Drug Application for a new dosage form and presentation (avutometinib 3.2 mg tablet co-packaged with defactinib 200 mg tablets) of the combination approved as NDA219616; application number not public (SRC-001, SRC-003, SRC-005).
- evidence class
- Formulation and presentation change at the approved dose and regimen; no new efficacy trial is named in the archived sources (SRC-003). Original approval rested on the single-arm phase 2 RAMP 201 study (SRC-003).
- pivotal n
- not applicable — no new efficacy study is named; the submission's bridging data are not described in the archived sources
- endpoint type
- not applicable — the application concerns formulation and packaging, not a new efficacy endpoint
- approved competitors in class
- none for this presentation; the capsule CO-PACK (NDA219616) is the sponsor's own approved product for KRAS-mutated recurrent LGSOC after prior systemic therapy (SRC-004, SRC-005)
- months since last guideline revision
- not applicable — no guideline is the subject of this proposition
- panel cycle position
- not applicable — the act is an FDA approval action
- sponsor request status
- NDA accepted 2026-10-07 with Priority Review; announced 2026-10-14; PDUFA date February 7, 2027 disclosed 2026-11-05 (SRC-001, SRC-002, SRC-003).
- odac referral
- none announced in the archived sources
- sponsor state change
- A chief executive transition effective 2027-01-01 and the termination of an at-the-market prospectus, both announced 2026-10-14 (SRC-001); neither is recorded as bearing on the application.
Sources
Everything the estimate was built from
Each was retrieved on or before the 2026-11-10 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.
-
SRC-001Verastem Form 8-K filed 2026-10-14. Item 8.01: on 2026-10-07 FDA accepted for review the company's Blister Pack New Drug Application, with action in the first quarter of 2027, and granted it Priority Review. Item 5.02: chief executive transition effective 2027-01-01; Item 8.01 also records termination of the at-the-market prospectus. -
SRC-002Exhibit 99.1 to Verastem's Form 10-Q filed 2026-11-05: Q3 2026 results release. FDA accepted the NDA for the AVMAPKI FAKZYNJA CO-PACK Blister Pack with Priority Review and an FDA decision by February 7, 2027; the current CO-PACK (avutometinib capsules; defactinib tablets) generated USD 24.0 million net product revenue in Q3 2026. -
SRC-003Exhibit 99.1 to Verastem's Form 8-K filed 2026-11-05: Q3 2026 corporate presentation. Slide 'AVMAPKI FAKZYNJA CO-PACK Blister Pack': FDA Priority Review granted, PDUFA date February 7, 2027; the proposed pack replaces four refrigerated 0.8 mg avutometinib capsules per dose with one 3.2 mg avutometinib tablet, with defactinib 200 mg tablets, standard and reduced dose packs and no refrigeration; 'Proposed formulation and packaging changes are subject to FDA approval.' RAMP 301 confirmatory trial design (avutometinib 3.2 mg twice weekly with defactinib 200 mg twice daily). -
SRC-004Verastem Form 10-Q for the quarter ended 2026-09-30, filed 2026-11-05: the marketed CO-PACK is approved by FDA for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy; in October 2026 FDA accepted the NDA for the Blister Pack with Priority Review and a decision expected by February 7, 2027; RAMP 301 topline expected mid-2027. -
SRC-005openFDA drugsfda products.active_ingredients.name:"AVUTOMETINIB", retrieved 2026-11-10: one application, NDA219616 (Verastem), AVMAPKI FAKZYNJA CO-PACK, capsule and tablet (avutometinib potassium eq 0.8 mg base; defactinib hydrochloride eq 200 mg base); ORIG 1 approved 2025-05-08; no supplement listed and no avutometinib tablet product. -
SRC-006openFDA drugsfda sponsor_name:"VERASTEM INC", retrieved 2026-11-10: one application, NDA219616; no other Verastem application. -
SRC-007openFDA drugsfda products.active_ingredients.name:"DEFACTINIB", retrieved 2026-11-10: one application, NDA219616; no other defactinib application.